C.OkpalaU
Clinical trials have demonstrated hemoglobin A1c reductions of approximately 2% in diabetes patients, with weight loss ranging from 7-11% in diabetes trials (SURPASS) and 15-21% in obesity trials (SURMOUNT), depending on the dose administered and patient population
Its always been the dream to have a small molecule version of a GLP-1 drug because not only can it now be taken orally, but also, small molecules are a lot easier to produce, McCoy says
Switching to semaglutide may help because the single-receptor approach sometimes produces milder GI effects, but the improvement is not guaranteed
We've ranked each use case as "Strong," "Moderate," or "Limited/Emerging" based on the quality and consistency of the data
Third-Party Testing: High-trust brands will have their products tested by independent labs to ensure that what is on the label matches what is in the bottle